GLP1R and diabetes mellitus: The ongoing semaglutide cardiovascular outcomes trial (SOUL) randomized clinical trial includes cognitive secondary endpoints that will provide key insights into the efficacy of GLP1 medications in reducing cognitive decline in patients with DM and established cardiovascular diseases including stroke [60].